UroGen Pharma announced strong preliminary results from its Phase 3 UTOPIA trial for UGN-103, showing a 77.8% three-month complete response rate for patients with recurrent low-grade intermediate-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback